Vogelmeier Respiratory Research 2014, 15:38 http://respiratory-research.com/content/15/1/38 COMMENTARY Open Access Systemic steroids in COPD-the beauty and the beast Claus F Vogelmeier1,2 The recommendations regarding the use of systemic ste- roids in COPD differ substantially depending on the phase of the disease. In moderate and severe acute exac- erbations oral steroids are advocated based on the find- ings of several placebo-controlled trials that have been performed in secondary-care settings: these studies showed that systemic steroids improve lung function, dyspnoea and gas exchange. In addition, steroid use re- sulted in fewer treatment failures, a lower relapse rate and shorter hospital stays [1-4]. Importantly, giving ste- roids orally is non-inferior to the i.v. application [5] and an 8-week treatment is not superior to a 2-week therapy [6]. Recently, it could even be shown that 5-day treat- ment is non-inferior to a 14-day course [7]. In the trial with longer term therapy [6] hyperglycemia requiring treatment was identified as considerable side effect, in the other trials no major adverse events were observed. In contrast, in stable COPD positive effects of systemic steroids are scarce: there is some evidence that higher doses (≥ 30 mg prednisolone/day) may improve lung function over a short period, whereas this was not ob- served in doses of less than 10–15 mg prednisolone/day [8]. In a 2-year trial with 5 mg prednisolone + 1600 μg budesonide/day efficacy regarding lung function decline was not significantly better than budesonide alone [9]. In addition, there are substantial side effect problems. In particular, it is well established that respiratory and per- ipheral muscle strength [10] are affected. This is caused by a myopathy that is characterized by atrophy and ne- crosis [11] and may lead to reduced survival. Besides, there is evidence that chronic therapy with systemic ste- roids is one of the risk factors for the high rate of osteo- porosis that is observed in COPD [12]. What does the paper by Horita et al. published in this issue of the journal [13] add to the literature? To my knowledge this is the first analysis that systematically evaluates the effects of systemic steroids on mortality in Correspondence: Claus.Vogelmeier@med.uni-marburg.de 1Department of Medicine, Pulmonary and Critical Care Medicine, 35033 Marburg, Germany 2Member of the German Center for Lung Research (DZL), University Medical Center Giessen and Marburg, Philipps-Universität Marburg, 35033 Marburg, Germany © 2014 Vogelmeier; licensee BioMed Central L Commons Attribution License (http://creativec reproduction in any medium, provided the or Dedication waiver (http://creativecommons.or unless otherwise stated. a considerable sample of COPD patients with severe and very severe COPD. The authors analyzed patients (N = 444) that had been randomized to the conservative treat- ment arm in the National Emphysema Treatment trial (NETT). They calculated a hazard ratio for death of 1.54 for the steroid user group. Then, in order to make sure that this result was not induced by unidentified con- founders they performed a propensity score matching. Based on this analysis the hazard ratio for death in the steroid group was 1.73. Thus, the observed effect seems to be robust and real. Nevertheless, the authors righteously mention several potential weaknesses of their study: a) it is not prospect- ive, but a prospective trial with this endpoint does not seem feasible, b) the steroid dose was not verified, c) only patients with an FEV1 ≤ 45% predicted had been in- cluded in the NETT trial, but logic tells that systemic steroids should only be considered when all other ther- apies are not sufficiently effective and it is quite unlikely that this occurs in patients with a moderate lung func- tion impairment. It is quite worrisome though that in the NETT trial only a minority of the patients were treated with long acting bronchodilators. In summary, the study results support the recommen- dations in guidelines and strategy documents to stay away from the chronic use of systemic steroids in COPD [14]. As a consequence, in patients in stable condition that are currently treated with systemic steroids this therapy should be tapered/stopped. This can be quite demanding: patients may develop fatigue, low blood pressure, joint pain, weakness and even psychotic symp- toms [15]. Importantly, discontinuation of chronic sys- temic steroid therapy did not result in an increase of COPD exacerbations [16]. There is only one scenario where steroid cessation may be harmful: some patients with an asthma-COPD overlap may profit from long- term use of systemic steroids [17] and may get worse when steroids are stopped. Based on the cited literature and supported by the findings of Horita et al. [13] there are some simple mes- sages regarding the use of systemic steroids in COPD: a) in moderate or severe acute exacerbations oral steroids td. This is an Open Access article distributed under the terms of the Creative ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and iginal work is properly credited. The Creative Commons Public Domain g/publicdomain/zero/1.0/) applies to the data made available in this article, mailto:Claus.Vogelmeier@med.uni-marburg.de http://creativecommons.org/licenses/by/4.0 http://creativecommons.org/publicdomain/zero/1.0/ Vogelmeier Respiratory Research 2014, 15:38 Page 2 of 2 http://respiratory-research.com/content/15/1/38 should be prescribed in a moderate dose (40 mg pred- nisolone) for 5 days, b) there is no place for systemic ste- roids in stable phase COPD, c) in patients treated with systemic steroids outside of an exacerbation steroid treatment should be withdrawn, d) before doing so ther- apy should be optimized and patients should be re- evaluated to make sure that they do not have an asthma- COPD overlap. Received: 10 March 2014 Accepted: 25 March 2014 Published: 3 April 2014 References 1. Thompson WH, Nielson CP, Carvalho P, Charan NB, Crowley JJ: Controlled trial of oral prednisone in outpatients with acute COPD exacerbation. Am J Respir Crit Care Med 1996, 154:407–412. 2. Davies L, Angus RM, Calverley PM: Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial. Lancet 1999, 354:456–460. 3. Maltais F, Ostinelli J, Bourbeau J, Tonnel AB, Jacquemet N, Haddon J, Rouleau M, Boukhana M, Martinot JB, Duroux P: Comparison of nebulized budesonide and oral prednisolone with placebo in the treatment of acute exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. Am J Respir Crit Care Med 2002, 165:698–703. 4. Aaron SD, Vandemheen KL, Hebert P, Dales R, Stiell IG, Ahuja J, Dickinson G, Brison R, Rowe BH, Dreyer J, Yetisir E, Cass D, Wells G: Outpatient oral prednisone after emergency treatment of chronic obstructive pulmonary disease. N Engl J Med 2003, 348:2618–2625. 5. de Jong YP, Uil SM, Grotjohan HP, Postma DS, Kerstjens HA, van den Berg JW: Oral or IV prednisolone in the treatment of COPD exacerbations: a randomized, controlled, double-blind study. Chest 2007, 132:1741–1747. 6. Niewoehner DE, Erbland ML, Deupree RH, Collins D, Gross NJ, Light RW, Anderson P, Morgan NA: Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. Department of veterans affairs cooperative study group. N Engl J Med 1999, 340:1941–1947. 7. Leuppi JD, Schuetz P, Bingisser R, Bodmer M, Briel M, Drescher T, Duerring U, Henzen C, Leibbrandt Y, Maier S, Miedinger D, Müller B, Scherr A, Schindler C, Stoeckli R, Viatte S, von Garnier C, Tamm M, Rutishauser J: Short-term vs conventional glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease: the REDUCE randomized clinical trial. JAMA 2013, 309:2223–22331. 8. Walters JA, Walters EH, Wood-Baker R: Oral corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2005, 3, CD005374. 9. Renkema TE, Schouten JP, Koëter GH, Postma DS: Effects of long-term treatment with corticosteroids in COPD. Chest 1996, 109:1156–1162. 10. Decramer M, Lacquet LM, Fagard R, Rogiers P: Corticosteroids contribute to muscle weakness in chronic airflow obstruction. Am J Respir Crit Care Med 1994, 150:11–16. 11. Decramer M, de Bock V, Dom R: Functional and histologic picture of steroid-induced myopathy in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1996, 153:1958–1964. 12. McEvoy CE, Ensrud KE, Bender E, Genant HK, Yu W, Griffith JM, Niewoehner DE: Association between corticosteroid use and vertebral fractures in older men with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998, 157:704–709. 13. Horita N, Miyazawa N, Morita S, Kojima R, Inoue M, Ishigatsubo Y, Kaneko T: Evidence suggesting that oral corticosteroids increase mortality in stable chronic obstructive pulmonary disease. Resp Res 2014, 15:37. 14. Vestbo J, Hurd SS, Agustí AG, Jones PW, Vogelmeier C, Anzueto A, Barnes PJ, Fabbri LM, Martinez FJ, Nishimura M, Stockley RA, Sin DD, Rodriguez-Roisin R: Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2013, 187:347–365. 15. Mercadante S, Villari P, Intravaia G: Withdrawal acute psychosis after corticosteroid discontinuation. J Pain Symptom Manage 2007, 34:118–119. 16. Rice KL, Rubins JB, Lebahn F, Parenti CM, Duane PG, Kuskowski M, Joseph AM, Niewoehner DE: Withdrawal of chronic systemic corticosteroids in patients with COPD: a randomized trial. Am J Respir Crit Care Med 2000, 162:174–178. 17. Postma DS, Steenhuis EJ, van der Weele LT, Sluiter HJ: Severe chronic airflow obstruction: can corticosteroids slow down progression? Eur J Respir Dis 1985, 67:56–64. doi:10.1186/1465-9921-15-38 Cite this article as: Vogelmeier: Systemic steroids in COPD-the beauty and the beast. Respiratory Research 2014 15:38. Submit your next manuscript to BioMed Central and take full advantage of: • Convenient online submission • Thorough peer review • No space constraints or color figure charges • Immediate publication on acceptance • Inclusion in PubMed, CAS, Scopus and Google Scholar • Research which is freely available for redistribution Submit your manuscript at www.biomedcentral.com/submit References